Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase

  • Authors:
    • Eiseki Usami
    • Michio Kimura
    • Mina Iwai
    • Hitomi Teramachi
    • Tomoaki Yoshimura
  • View Affiliations

  • Published online on: April 28, 2017     https://doi.org/10.3892/mco.2017.1232
  • Pages: 955-959
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to assess the incidence of tumor lysis syndrome (TLS) in patients with hematological malignancies treated with rasburicase, and to evaluate the dose and duration of rasburicase administration. A total of 52 patients were enrolled. The background of the patients, incidence of TLS and laboratory data were retrospectively examined; in addition, the dose and duration of rasburicase administration and the factors affecting the onset of TLS were evaluated and compared among TLS risk categories. During the study period, 2 (3.8%) of the patients developed clinical TLS and 24 (46.2%) developed laboratory TLS (LTLS). Although the LTLS rate was very high, there were no life‑threatening cases of TLS. The median daily dose of rasburicase administered to all patients was 7.5 mg/day (interquartile range, 7.5‑9.0 mg/day), and the daily weight‑based dose was 0.147 mg/kg/day (range, 0.126‑0.178 mg/kg/day). The administration duration was 3 days (interquartile range, 3‑4 days). Additionally, there was no significant association between TLS risk classification and daily rasburicase administration dose, duration, or post‑administration laboratory data. The factors affecting the onset of TLS included serum uric acid level, as well as serum creatinine and phosphate levels. Rasburicase was highly effective in the prevention and management of hyperuricemia, even at a low‑dose (7.5 mg/day) and a duration that was 3 days shorter compared with that recommended by the manufacturer. Therefore, clinicians should administer rasburicase based on their clinical judgment, taking into consideration the cost‑effectiveness of this therapy.
View References

Related Articles

Journal Cover

June-2017
Volume 6 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Usami E, Kimura M, Iwai M, Teramachi H and Yoshimura T: Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase. Mol Clin Oncol 6: 955-959, 2017
APA
Usami, E., Kimura, M., Iwai, M., Teramachi, H., & Yoshimura, T. (2017). Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase. Molecular and Clinical Oncology, 6, 955-959. https://doi.org/10.3892/mco.2017.1232
MLA
Usami, E., Kimura, M., Iwai, M., Teramachi, H., Yoshimura, T."Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase". Molecular and Clinical Oncology 6.6 (2017): 955-959.
Chicago
Usami, E., Kimura, M., Iwai, M., Teramachi, H., Yoshimura, T."Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase". Molecular and Clinical Oncology 6, no. 6 (2017): 955-959. https://doi.org/10.3892/mco.2017.1232